


Amendment to the Claims:

Claim 5 has been amended.

Claim 1. (previously presented): A compound of Formula I:



or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR_a, wherein R_a is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_a, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NHCO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy;

R₂ is

hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R₃ is

a direct link or

C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ carboxyalkyl; and

A₂ is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or


more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -N(R₁)COR_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, NHSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d; or

-COR_c, -COOR_c or -CONR_cR_d, wherein

R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 2. (previously presented): A compound of Formula II:



or pharmaceutically acceptable salt thereof, wherein

R is

-COR_a, -CONR_aR_b, -SO₂R_a or -PO₃R_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;

A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, -NHSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d, wherein R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is
hydrogen, alkyl, hydroxy or alkoxy;

R₂ is
hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl,
heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R₃ is
a direct link or
C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ carboxyalkyl; and


A₂ is
phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or
more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy,
arylalkoxy, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -N(R₁)COR_e, -SO₂R_e, -SO₃R_e or
-SO₂NR_eR_f;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring
having from one to four heteroatoms selected from N, O or S, and may be optionally
substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy,
-CF₃, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -NHCOR_eR_f, NHSO₂R_a, -SO₂R_a, -SO₃R_a
or -SO₂NR_aR_b; or

-COR_e, -COOR_e or -CONR_eR_f, wherein

R_e and R_f are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl
or heteroaryl.

Claim 3. (previously presented): A compound of Formula III:



or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR_a, wherein R_a is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;


A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_a, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NHSO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy; and

R₂ is



wherein

R_c and R_d are independently hydrogen or alkyl;

X is N, O or S; and


A₂ is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -N(R₁)COR_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -NHCOR_eR_f, -NHSO₂R_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f, wherein

R_e and R_f are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 4. (previously presented): A compound of Formula IV:



or pharmaceutically acceptable salt thereof, wherein

R is

-COR_a, -CONR_aR_b, -SO₂R_a or -PO₃R_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;


A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, -NHSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d, wherein R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy; and

R₂ is



wherein

R_e and R_f are independently hydrogen or alkyl;

X is N, O or S; and

A₂ is


phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_g, -COOR_g, -CONR_gR_h, -N(R₁)COR_g, -SO₂R_g, -SO₃R_g or -SO₂NR_gR_h; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_g, -COOR_g, -CONR_gR_h, -NHCOR_gR_h, NHCO₂R_g, -SO₂R_g, -SO₃R_g or -SO₂NR_gR_h, wherein

R_g and R_h are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

Claim 5. (currently amended): A compound of claim 1, wherein

A₁ is




wherein R_j, R_a and R_j, R_b are independently -H, -C₁₋₆ alkyl, or -CO₂-alkyl or -CO₂-CH₂CH₂NH₂;

R₁ is -H;

R₂ is

-H, -Me, -Et,




wherein R_c is alkyl;

R_3 is

$-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}(\text{CH}_3)-$, $-\text{C}(\text{CH}_3)_2-$, $-\text{CH}(\text{CH}_2\text{OH})-$ or
 $-\text{CH}(\text{CH}_2\text{CH}_2\text{COOH})-$; and

A_2 is



wherein X is O or S.

Claim 6. (previously presented): A compound of Formula I according to claim 1,
 selected from

4-(Benzothiazol-6-ylamino)-6-(ethyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(methyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(benzylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(methyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(ethyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-chloro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-fluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(pyridin-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2,6-difluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[methyl-(2-pyridin-2-yl-ethyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[pyridin-2-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(1-benzyl-pyrrolidin-3-yl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-fluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-chloro-6-methyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(N'-methyl-N'-phenyl-hydrazino)-[1,3,5]triazin-2-ol;
4-(benzothiazol-6-ylamino)-6-[(pyridin-4-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-Benzothiazol-6-ylamino)-6-(2-pyridin-3-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-Benzothiazol-6-ylamino)-6-(1-phenyl-propylamino)-[1,3,5]triazin-2-ol;
4-Benzothiazol-6-ylamino)-6-(2-pyridin-2-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-naphthalen-1-yl-ethylamino)-[1,3,5]triazin-2-ol;

4-(Benzothiazol-6-ylamino)-6-(3-hydroxymethyl-phenylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(quinolin-5-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(4-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(1H-indazol-6-yl)-methylamino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(6-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-hydroxy-phenylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[2-(2-hydroxyethyl)-phenylamino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(5-thiophen-2-yl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol; 4-
(Benzothiazol-6-ylamino)-6-(2-phenyl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2,4-difluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-phenylamino-[1,3,5]triazin-2-ol;
4-(1H-Indazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-hydroxy-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(1H-Indazol-5-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-7-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(furan-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(thiophen-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(furan-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(thiophen-3-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(benzyl-pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ol;
3-{[4-(Benzothiazol-6-ylamino)-6-hydroxy-[1,3,5]triazin-2-yl]-benzylamino}-propane-1,2-diol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-morpholin-4-ylpropyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-{benzyl-[3-(4-methyl-piperazin-1-yl)-propyl]-amino}-
[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-dimethylamino-propyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-piperazin-1-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-

(Benzothiazol-6-ylamino)-6-[benzyl-(2-morpholin-4-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-dimethylamino-ethyl)-amino]-[1,3,5]triazin-2-ol; 4-(2-Amino-benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol; 4-(1-Methyl-1-phenylethylamino)-6-(quinolin-6-ylamino)-[1,3,5]triazin-2-ol; 4-(Quinolin-6-ylamino)-6-(N-ethylbenzylamino)-[1,3,5]triazin-2-ol; 4-(Quinolin-6-ylamino)-6-(N-methylbenzylamino)-[1,3,5]triazin-2-ol; 4-(Quinolin-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol; N-[4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-yl]-hydroxylamine; or a pharmaceutically acceptable salt thereof.

Claim 7. (previously presented): A compound of Formula III according to claim 3, selected from

4-(Benzothiazol-6-yl-amino)-6-(2-methyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-benzyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2,6-dimethyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2,5-dimethyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(3-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(3-methyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(morpholin-4-yl)-[1,3,5]triazine-2-ol;
or a pharmaceutically acceptable salt thereof.

Claim 8. (original): A pharmaceutical composition, comprising a compound of any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

Claim 9. (original): A pharmaceutical composition, comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

Claim 10. (original): A pharmaceutical composition, comprising a compound of claim 6 or 7 and a pharmaceutically acceptable carrier.

Claim 11. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine; and
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

Claim 12. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of:

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and
- d) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-

hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)- [1,3,5]triazine, respectively.

Claim 13. (original): A method of claim 11 or 12, wherein the displaceable groups are chlorines.

Claim 14. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and

cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

Claim 15. (original): A method of preparing the compounds of Formulae I and III where R is -NHOH, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and

cc) displacing the third displaceable group with hydroxylamine under acidic conditions to give a 4,6-diamino-([1,3,5]triazin-2-yl)-hydroxylamine.

Claim 16. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of:

- aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;
- bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine;
- cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and
- dd) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)-[1,3,5]triazine, respectively.

Claims 17 to 30 (cancelled).

Claim 31. (previously presented): A method of treating breast cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

Claim 32. (previously presented): A method of treating breast cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

Claim 33. ((previously presented): A method of treating breast cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

Claims 34 to 42. (cancelled).

Claim 43. (original): A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier and from about 0.5 mg to about 10 g of at least one compound of any one of

claims 1 to 7.

Claim 44. (original): A dosage form according to claim 43 adapted for parenteral or oral administration.